Neurocrine Biosciences (NBIX) 49.75 $NBIX Neuro
Post# of 273322
Posted On: 07/29/2015 1:42:29 PM
Neurocrine Biosciences (NBIX) 49.75 $NBIX
Neurocrine Biosciences Shares Up 25.4% Since SmarTrend's Buy Recommendation (NBIX)
Comtex SmarTrend(R) - Tue Jul 28, 5:54PM CDT
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on May 13th, 2015 at $41.40. In approximately 3 months, Neurocrine Biosciences has returned 25.43% as of today's recent price of $51.92.
NBIX: 49.75 (-2.17)
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 156.57 (-3.75), BIIB: 311.67 (-8.26), NBIX: 49.75 (-2.17), ISIS: 52.44 (-1.96), SRPT: 31.54 (-0.49), RCPT: 227.90 (+0.74)
Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2015 Results
PR Newswire - Wed Jul 22, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2015 financial results after the Nasdaq market closes on Wednesday, July 29, 2015. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, July 29, 2015 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 49.75 (-2.17)
Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H1 2015 - 23 Companies & 29 Drug Profiles
M2 - Tue Jul 21, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hs6grh/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ascendis Pharma A/S - AstraZeneca PLC - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Eli Lilly and Company - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - MarcoPolo Pharmaceuticals SA - Navigen Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited Drug Profiles - ACP-005 - aripiprazole - aripiprazole CR - BRDK-98958073 - cariprazine - CNV-1061436 - DP-VPA - Drug for Bipolar Disorder - Drug for Cancer and Neurodegenerative Disease - Endoxifen - ITI-007 - KP-303 - lurasidone hydrochloride - LY-2979165 - NP-202 - paliperidone palmitate - PGW-5 - quetiapine fumarate ER - ramelteon - risperidone - RP-5063 - SKL-PSY - Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - uridine triacetate - ziprasidone hydrochloride For more information visit http://www.researchandmarkets.com/research/hs...r_disorder
NBIX: 49.75 (-2.17), KMPH: 16.89 (-0.17), ASND: 19.71 (-0.56), ZGNX: 19.44 (-0.70), PFE: 35.71 (+0.36), AZN: 32.95 (+0.14), TEVA: 71.08 (-0.33), ITCI: 29.44 (-1.78), LLY: 85.06 (-0.62), OMER: 16.06 (-0.30)
Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019 - GlaxoSmithKline, Pfizer & Otsuka Pharmaceutical Dominate the Industry
M2 - Mon Jul 20, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3pt8vd/global) has announced the addition of the "Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019" report to their offering. The global PTSD therapeutics market to grow at a CAGR of 1.09% over the period 2014-2019. This report covers the present scenario and the growth prospects of the global PTSD therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of PTSD. This report includes the segmentation of the market based on geography. Strategic alliances formed, in terms of licensing and collaboration, to help in the co-development and commercialization of drugs in different regions is one of the key trends in the market. Co-development agreements between different companies enable the use of technical expertise from both companies. These agreements also allow the use of regulatory and development experience gained by one company for the support of the pipeline candidates of another company. According to the report, increased cases of accidents and violence boost market growth. The rise in conflicts between different countries has increased stress levels in individuals worldwide, particularly those in the military. Domestic and social violence also trigger the development of PTSD in people. Further, the report states that the unavailability of standard diagnostic methods to identify PTSD in people hinders market growth. Currently, the diagnosis is based on criteria set by the American Psychiatric Association; determining patient conformance to the criteria is time-consuming and can lead to misdiagnosis, resulting in inadvertent noncompliance among the population. Key Vendors - GlaxoSmithKline - Pfizer - Otsuka Pharmaceutical Other Prominent Vendors - Azevan Pharmaceuticals - Baylor Research Institute - Eli Lilly - Forest Laboratories - H. Lundbeck - Humanetics Pharmaceuticals - Marinus Pharmaceuticals - Nanotherapeutics - Neurocrine Biosciences - Novartis Pharmaceuticals - Synchroneuron - Tonix Pharmaceuticals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Product Profiles - Introduction - PTSD Overview - Pipeline Analysis - Market Landscape - Market Segmentation by Class of Drug - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and Their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and Their Impact - Vendor Landscape - Global PTSD Therapeutics Market: Key Takeaways - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/3pt8vd/global
NBIX: 49.75 (-2.17), MRNS: 14.75 (-0.23), LLY: 85.06 (-0.62), GSK: 42.78 (+1.07), NVS: 103.80 (+1.01)
Neurocrine Biosciences Up 27.4% Since SmarTrend Uptrend Call (NBIX)
Comtex SmarTrend(R) - Tue Jul 14, 11:35AM CDT
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on May 13th, 2015 at $41.40. In approximately 2 months, Neurocrine Biosciences has returned 27.43% as of today's recent price of $52.75.
NBIX: 49.75 (-2.17)
Uptrend Call Working As Neurocrine Biosciences Stock Rises 16.7% (NBIX)
Comtex SmarTrend(R) - Tue Jul 07, 10:33AM CDT
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on May 13th, 2015 at $41.40. In approximately 2 months, Neurocrine Biosciences has returned 16.73% as of today's recent price of $48.32.
NBIX: 49.75 (-2.17)
Aduro Biotech elects Dr. Stephen Sherwin to board
M2 - Mon Jun 29, 3:07AM CDT
Oncology company Aduro Biotech (NasdaqGS:ADRO) reported on Friday the addition of Stephen Sherwin, M.D., to its board of directors, increasing the number of directors from six to seven.
VICL: 0.62 (-0.02), NBIX: 49.75 (-2.17), ADRO: 26.34 (-0.24), RIGL: 2.81 (-0.12)
15.2% Return Seen to Date on SmarTrend Neurocrine Biosciences Call (NBIX)
Comtex SmarTrend(R) - Fri Jun 19, 9:38AM CDT
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on May 13th, 2015 at $41.40. In approximately 1 month, Neurocrine Biosciences has returned 15.21% as of today's recent price of $47.69.
NBIX: 49.75 (-2.17)
After Yesterday's Rally of 6.41% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Jun 16, 4:43PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $42.50 to a high of $46.69. Yesterday, the shares gained 6.4%, which took the trading range above the 3-day high of $43.71 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 49.75 (-2.17)
Teva's Auspex Buyout Pays, But Mylan Bid Hits Snag
at Investor's Business Daily - Tue Jun 16, 2:39PM CDT
Israeli drug giant Teva Pharmaceutical Industries (TEVA) reported positive results for a recently acquired drug Tuesday. Teva stock was down a fraction, however, as the company also faced a new roadblock in its effort to take over Mylan (MYL). Teva...
ABT: 51.01 (+0.07), PRGO: 192.33 (+0.26), NBIX: 49.75 (-2.17), MYL: 57.13 (+0.78), TEVA: 71.08 (-0.33)
A Small Stumble For Neurocrine Biosciences Changes Little
Stephen Simpson, CFA - at Seeking Alpha - Tue Jun 09, 3:21PM CDT
NBIX: 49.75 (-2.17)
Shares of NBIX Up 4.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jun 09, 9:31AM CDT
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on May 13th, 2015 at $41.40. In approximately 4 weeks, Neurocrine Biosciences has returned 4.65% as of today's recent price of $43.32.
NBIX: 49.75 (-2.17)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Jun 09, 8:17AM CDT
FCEL: 0.87 (+0.02), SAGE: 68.53 (-4.30), NBIX: 49.75 (-2.17), NAVB: 1.72 (unch), AU: 6.44 (+0.12), ZQK: 0.48 (-0.04), MXL: 11.04 (-0.03), AMPE: 2.71 (-0.08), AXN: 1.82 (+0.02), BURL: 55.17 (+0.78), AUDC: 2.71 (-0.09), OCLS: 1.87 (+0.26), WBAI: 18.52 (-0.08)
NEUROCRINE BIOSCIENCES
at Investor's Business Daily - Mon Jun 08, 6:01PM CDT
NEUROCRINE BIOSCIENCES (NBIX) fell 4.7% to 43.15 after it suspended 2 studies of a treatment for congenital adrenal hyperplasia . The FDA said that the program would be placed on partial clinical hold.
NBIX: 49.75 (-2.17)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 4:37PM CDT
ROKA: 3.09 (+0.02), KRNT: 14.37 (-0.22), TTMI: 9.24 (+0.08), NBIX: 49.75 (-2.17), KTOS: 5.64 (+0.15), HQY: 33.83 (-0.13), SSRI: 5.81 (+0.36), MLNK: 3.25 (+0.04), DEPO: 31.86 (-1.03), CASY: 100.18 (+0.06)
Neurocrine Biosciences Provides Update on NBI-77860 Program for Congenital Adrenal Hyperplasia
PR Newswire - Mon Jun 08, 3:27PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has suspended two planned clinical studies of the Company's CRF antagonist NBI-77860.
NBIX: 49.75 (-2.17)
Global Tourette Syndrome Pipeline Review, H1 2015 - 9 Companies & 10 Drug Profiles
M2 - Mon Jun 08, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbs28p/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Edison Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Otsuka Holdings Co., Ltd. - Psyadon Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Synchroneuron Inc. Drug Profiles - acamprosate calcium SR - aripiprazole - AZD-5213 - CPP-115 - dutetrabenazine ER - ecopipam hydrochloride - RP-5063 - valbenazine - vatiquinone - vigabatrin For more information visit http://www.researchandmarkets.com/research/vb...e_syndrome
NBIX: 49.75 (-2.17), CPRX: 5.03 (-0.20), AZN: 32.95 (+0.14), ASPX: 100.96 (unch)
Neurocrine Biosciences Shares Up 25.4% Since SmarTrend's Buy Recommendation (NBIX)
Comtex SmarTrend(R) - Tue Jul 28, 5:54PM CDT
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on May 13th, 2015 at $41.40. In approximately 3 months, Neurocrine Biosciences has returned 25.43% as of today's recent price of $51.92.
NBIX: 49.75 (-2.17)
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 156.57 (-3.75), BIIB: 311.67 (-8.26), NBIX: 49.75 (-2.17), ISIS: 52.44 (-1.96), SRPT: 31.54 (-0.49), RCPT: 227.90 (+0.74)
Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2015 Results
PR Newswire - Wed Jul 22, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2015 financial results after the Nasdaq market closes on Wednesday, July 29, 2015. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, July 29, 2015 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 49.75 (-2.17)
Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H1 2015 - 23 Companies & 29 Drug Profiles
M2 - Tue Jul 21, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hs6grh/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ascendis Pharma A/S - AstraZeneca PLC - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Eli Lilly and Company - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - MarcoPolo Pharmaceuticals SA - Navigen Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited Drug Profiles - ACP-005 - aripiprazole - aripiprazole CR - BRDK-98958073 - cariprazine - CNV-1061436 - DP-VPA - Drug for Bipolar Disorder - Drug for Cancer and Neurodegenerative Disease - Endoxifen - ITI-007 - KP-303 - lurasidone hydrochloride - LY-2979165 - NP-202 - paliperidone palmitate - PGW-5 - quetiapine fumarate ER - ramelteon - risperidone - RP-5063 - SKL-PSY - Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - uridine triacetate - ziprasidone hydrochloride For more information visit http://www.researchandmarkets.com/research/hs...r_disorder
NBIX: 49.75 (-2.17), KMPH: 16.89 (-0.17), ASND: 19.71 (-0.56), ZGNX: 19.44 (-0.70), PFE: 35.71 (+0.36), AZN: 32.95 (+0.14), TEVA: 71.08 (-0.33), ITCI: 29.44 (-1.78), LLY: 85.06 (-0.62), OMER: 16.06 (-0.30)
Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019 - GlaxoSmithKline, Pfizer & Otsuka Pharmaceutical Dominate the Industry
M2 - Mon Jul 20, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3pt8vd/global) has announced the addition of the "Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019" report to their offering. The global PTSD therapeutics market to grow at a CAGR of 1.09% over the period 2014-2019. This report covers the present scenario and the growth prospects of the global PTSD therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of PTSD. This report includes the segmentation of the market based on geography. Strategic alliances formed, in terms of licensing and collaboration, to help in the co-development and commercialization of drugs in different regions is one of the key trends in the market. Co-development agreements between different companies enable the use of technical expertise from both companies. These agreements also allow the use of regulatory and development experience gained by one company for the support of the pipeline candidates of another company. According to the report, increased cases of accidents and violence boost market growth. The rise in conflicts between different countries has increased stress levels in individuals worldwide, particularly those in the military. Domestic and social violence also trigger the development of PTSD in people. Further, the report states that the unavailability of standard diagnostic methods to identify PTSD in people hinders market growth. Currently, the diagnosis is based on criteria set by the American Psychiatric Association; determining patient conformance to the criteria is time-consuming and can lead to misdiagnosis, resulting in inadvertent noncompliance among the population. Key Vendors - GlaxoSmithKline - Pfizer - Otsuka Pharmaceutical Other Prominent Vendors - Azevan Pharmaceuticals - Baylor Research Institute - Eli Lilly - Forest Laboratories - H. Lundbeck - Humanetics Pharmaceuticals - Marinus Pharmaceuticals - Nanotherapeutics - Neurocrine Biosciences - Novartis Pharmaceuticals - Synchroneuron - Tonix Pharmaceuticals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Product Profiles - Introduction - PTSD Overview - Pipeline Analysis - Market Landscape - Market Segmentation by Class of Drug - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and Their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and Their Impact - Vendor Landscape - Global PTSD Therapeutics Market: Key Takeaways - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/3pt8vd/global
NBIX: 49.75 (-2.17), MRNS: 14.75 (-0.23), LLY: 85.06 (-0.62), GSK: 42.78 (+1.07), NVS: 103.80 (+1.01)
Neurocrine Biosciences Up 27.4% Since SmarTrend Uptrend Call (NBIX)
Comtex SmarTrend(R) - Tue Jul 14, 11:35AM CDT
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on May 13th, 2015 at $41.40. In approximately 2 months, Neurocrine Biosciences has returned 27.43% as of today's recent price of $52.75.
NBIX: 49.75 (-2.17)
Uptrend Call Working As Neurocrine Biosciences Stock Rises 16.7% (NBIX)
Comtex SmarTrend(R) - Tue Jul 07, 10:33AM CDT
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on May 13th, 2015 at $41.40. In approximately 2 months, Neurocrine Biosciences has returned 16.73% as of today's recent price of $48.32.
NBIX: 49.75 (-2.17)
Aduro Biotech elects Dr. Stephen Sherwin to board
M2 - Mon Jun 29, 3:07AM CDT
Oncology company Aduro Biotech (NasdaqGS:ADRO) reported on Friday the addition of Stephen Sherwin, M.D., to its board of directors, increasing the number of directors from six to seven.
VICL: 0.62 (-0.02), NBIX: 49.75 (-2.17), ADRO: 26.34 (-0.24), RIGL: 2.81 (-0.12)
15.2% Return Seen to Date on SmarTrend Neurocrine Biosciences Call (NBIX)
Comtex SmarTrend(R) - Fri Jun 19, 9:38AM CDT
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on May 13th, 2015 at $41.40. In approximately 1 month, Neurocrine Biosciences has returned 15.21% as of today's recent price of $47.69.
NBIX: 49.75 (-2.17)
After Yesterday's Rally of 6.41% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Jun 16, 4:43PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $42.50 to a high of $46.69. Yesterday, the shares gained 6.4%, which took the trading range above the 3-day high of $43.71 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 49.75 (-2.17)
Teva's Auspex Buyout Pays, But Mylan Bid Hits Snag
at Investor's Business Daily - Tue Jun 16, 2:39PM CDT
Israeli drug giant Teva Pharmaceutical Industries (TEVA) reported positive results for a recently acquired drug Tuesday. Teva stock was down a fraction, however, as the company also faced a new roadblock in its effort to take over Mylan (MYL). Teva...
ABT: 51.01 (+0.07), PRGO: 192.33 (+0.26), NBIX: 49.75 (-2.17), MYL: 57.13 (+0.78), TEVA: 71.08 (-0.33)
A Small Stumble For Neurocrine Biosciences Changes Little
Stephen Simpson, CFA - at Seeking Alpha - Tue Jun 09, 3:21PM CDT
NBIX: 49.75 (-2.17)
Shares of NBIX Up 4.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jun 09, 9:31AM CDT
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on May 13th, 2015 at $41.40. In approximately 4 weeks, Neurocrine Biosciences has returned 4.65% as of today's recent price of $43.32.
NBIX: 49.75 (-2.17)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Jun 09, 8:17AM CDT
FCEL: 0.87 (+0.02), SAGE: 68.53 (-4.30), NBIX: 49.75 (-2.17), NAVB: 1.72 (unch), AU: 6.44 (+0.12), ZQK: 0.48 (-0.04), MXL: 11.04 (-0.03), AMPE: 2.71 (-0.08), AXN: 1.82 (+0.02), BURL: 55.17 (+0.78), AUDC: 2.71 (-0.09), OCLS: 1.87 (+0.26), WBAI: 18.52 (-0.08)
NEUROCRINE BIOSCIENCES
at Investor's Business Daily - Mon Jun 08, 6:01PM CDT
NEUROCRINE BIOSCIENCES (NBIX) fell 4.7% to 43.15 after it suspended 2 studies of a treatment for congenital adrenal hyperplasia . The FDA said that the program would be placed on partial clinical hold.
NBIX: 49.75 (-2.17)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 4:37PM CDT
ROKA: 3.09 (+0.02), KRNT: 14.37 (-0.22), TTMI: 9.24 (+0.08), NBIX: 49.75 (-2.17), KTOS: 5.64 (+0.15), HQY: 33.83 (-0.13), SSRI: 5.81 (+0.36), MLNK: 3.25 (+0.04), DEPO: 31.86 (-1.03), CASY: 100.18 (+0.06)
Neurocrine Biosciences Provides Update on NBI-77860 Program for Congenital Adrenal Hyperplasia
PR Newswire - Mon Jun 08, 3:27PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has suspended two planned clinical studies of the Company's CRF antagonist NBI-77860.
NBIX: 49.75 (-2.17)
Global Tourette Syndrome Pipeline Review, H1 2015 - 9 Companies & 10 Drug Profiles
M2 - Mon Jun 08, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbs28p/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Edison Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Otsuka Holdings Co., Ltd. - Psyadon Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Synchroneuron Inc. Drug Profiles - acamprosate calcium SR - aripiprazole - AZD-5213 - CPP-115 - dutetrabenazine ER - ecopipam hydrochloride - RP-5063 - valbenazine - vatiquinone - vigabatrin For more information visit http://www.researchandmarkets.com/research/vb...e_syndrome
NBIX: 49.75 (-2.17), CPRX: 5.03 (-0.20), AZN: 32.95 (+0.14), ASPX: 100.96 (unch)
(0)
(0)